S1Tx is in preclinical stage developing FDA/EMA-approved, cannabis-based therapies.

We have patentable preclinical discoveries and are one of the few US firms doing federally authorized cannabis R&D -- a rare advantage enabling drug discovery.

We are developing THC+CBD to treat a rare and common type of migraine, the world's 3rd largest disease. Lead optimization studies are underway in the U.S./E.U.